Background: Telavancin, a new multifunctional lipoglycopeptide antibiotic, exhibits broad-spectrum Gram-positive activity against a variety of pathogens. We examined the effects of human serum and antimicrobial concentrations on the activity of telavancin against glycopeptide-intermediate staphylococcal species (GISS), heteroresistant GISS (hGISS) and three vancomycin-resistant Staphylococcus aureus (VRSA) compared with vancomycin, quinupristin/dalfopristin, linezolid and daptomycin.
Introduction
Staphylococcus aureus has long been recognized as a serious pathogen responsible for a variety of human infections. Since the first report of methicillin resistance in the early 1960s, resistance associated with this pathogen has continued to increase worldwide. 1, 2 Until recently, all S. aureus remained susceptible to vancomycin, the first clinically available glycopeptide. The increase in incidence of methicillin-resistant S. aureus (MRSA) worldwide has led to a dramatic rise in the use of vancomycin. An apparent consequence of sustained vancomycin prescribing pressure has been the development of a variety of staphylococci with reduced susceptibilities to vancomycin. These include glycopeptideintermediate susceptible staphylococcal species (GISS) with MICs of 8-16 mg/L, heteroresistant staphylococcal species (hGISS) with MICs of 1-4 mg/L, and, the most worrisome, vancomycin-resistant S. aureus (VRSA), with MICs of 1024, 32, 64 and 256 mg/L, which have been reported recently. [1] [2] [3] [4] [5] [6] [7] [8] [9] Telavancin, a new lipoglycopeptide antimicrobial agent, is being investigated as a potential alternative treatment for resistant Gram-positive bacterial pathogens. Telavancin is rapidly bactericidal and demonstrates concentration-dependent effects. Recent pharmacokinetic data in healthy volunteers demonstrate achievable serum concentrations between 80 and 155 mg/L with a half-life of around 8 h, allowing for convenient once-daily administration. 10 Similar to the approved glycopeptides vancomycin and teicoplanin, telavancin inhibits peptidoglycan synthesis. However, unlike these agents, telavancin also perturbs bacterial plasma membrane function, including dissipation of membrane potential and increases in permeability.
11 This intramolecular synergy has been proposed as a possible mechanism to minimize the development of further resistance in these organisms. 10 Studies in vitro have demonstrated that telavancin possesses bactericidal activity with post-antibiotic effects against many strains of Gram-positive organisms including MRSA and GISS. 10, 12, 13 Both telavancin and daptomycin have been noted to be highly protein bound, 93% and 92%, respectively. 10, 14 Pharmacokinetic studies in healthy volunteers along with documentation of concentration-dependent killing support once-daily administration. 10, 13 The primary objective of the present study was to compare the in vitro activity of telavancin against GISS, hGISS and VRSA with those of vancomycin, linezolid, quinupristin/dalfopristin and daptomycin. Additionally, the effects of protein on the bactericidal properties at varying concentrations of telavancin were investigated. 
Materials and methods

Bacterial strains and antimicrobials
Medium
Mueller-Hinton broth (MHB; Difco Laboratories, Detroit, MI, USA) supplemented with magnesium (12.5 mg/L) and calcium (25 mg/L) (SMHB) was used for vancomycin, linezolid, quinupristin/ dalfopristin and telavancin microdilution susceptibility testing and time-kill experiments. MHB, adjusted to contain the normal physiological calcium concentration (1.1-1.3 mmol/L), was used for all daptomycin experiments. Sigma S-7023 Human Serum (Sigma-Aldrich, St Louis, MO, USA) at 50% v/v was combined with SMHB for telavancin and daptomycin susceptibility and timekill experiments. Processing of the serum included heating to 56 C for 1 h and then passage through 0.8, 0.5 and 0.22 micron filters.
15
Brain-heart infusion agar (BHI; Becton-Dickinson, Sparks, MD, USA) for the representative GISS and VRSA isolates was used for bacterial quantification of samples from time-kill experiments.
Susceptibility testing
The MIC and MBC for each isolate was determined using microdilution technique with an inoculum of 5 · 10 5 cfu/mL according to the Clinical and Laboratory Standards Institute guidelines and incubated for 24 h at 35 C. 15 Samples (5 mL) from visually clear wells were plated onto BHI plates for the determination of MBCs, and all samples were incubated for 24 h at 35 C. MICs and MBCs were determined in duplicate. Telavancin and daptomycin MICs and MBCs in addition were determined in the presence of SMHB or SMHB-Ca 2+ (daptomycin) combined with 50% human serum.
Time-kill curves
Time-kill experiments were performed in triplicate for all antibiotics against two GISS and two VRSA strains. Time-kill curve experiments for telavancin and daptomycin were performed in the presence and absence of serum. Using a starting bacterial density of 1 · 10 8 cfu/mL during mid-exponential phase, the organism was diluted to 5 · 10 6 cfu/mL into each of the different growth media and the growth control. Mid-exponential phase was determined by obtaining spectrometer readings of OD 0.3 at 625 nm, which corresponds to 1 · 10 8 cfu/mL. Telavancin, along with each of the other drugs, was tested at concentrations of 1·, 2·, 4·, 8·, 16· and 32· the respective MIC against the GISS and VRSA. Various concentrations of telavancin were used to evaluate organism killing along with the extent of protein binding and concentration dependent activity of the compound. Aliquots (0.1 mL) were removed from cultures at 0, 1, 4, 8 and 24 h and diluted in 0.9% sodium chloride for colony counting. Colony counts were performed on BHI using an automatic spiral plater (DW Scientific; Frederick, MD, USA) followed by incubation at 35 C for 24 h. We determined these methods to have a lower limit of reliable detection of 2 log 10 cfu/mL. Time-kill curves were constructed by plotting mean colony counts (log 10 cfu/mL) versus time. In order to account for antibiotic carryover, all samples were diluted and/or filtered sufficiently prior to plating, therefore reducing the antibiotic concentration below the MIC of the drug. Bactericidal activity was defined as a >3 log 10 cfu/mL reduction in bacterial density (99.9% kill) from the starting inoculum. Time to 99.9% kill (T 99.9 ) was determined by linear regression of the sample points if r 2 ‡ 0.95 or by visual inspection.
Statistical analysis
All statistical analyses were performed using SPSS statistical software (release 11.5.2.1; SPSS, Inc. Chicago, IL, USA). Colony counts at 24 h were compared between groups using one-way ANOVA followed by Tukey's post hoc test for multiple comparisons. A P value of £0.05 indicated statistical significance.
Results
Susceptibility results
Telavancin, daptomycin and quinupristin/dalfopristin demonstrated potent activity against all GISS and hGISS organisms tested. All organisms were susceptible to linezolid as well.
Results for MIC 50 and MIC 90 , the MIC range and MBC ranges are shown in Table 1 . The MIC and MBC for the two GISS and VRSA utilized in the time-kill analysis are summarized in Table 2 . In the presence of serum the MIC of telavancin was noted to increase 2-to 8-fold (Table 1) regardless of the organism. Like telavancin, daptomycin also demonstrated an increase in MICs (1-to 4-fold) in the presence of human serum.
Time-kill curve results
Time-kill curves were constructed for Mu50, NJ992, VRSA MI and VRSA PA (see Tables 3-5 ). In general telavancin, daptomycin, both with and without serum, and quinupristin/dalfopristin demonstrated concentration-dependent activity against all organisms. Linezolid exhibited bacteriostatic activity at 4-8·MIC against tested organisms. Representative antimicrobial comparative kill curves at 8· MIC are shown in Figure 1 . Telavancin demonstrated bactericidal activity at concentrations of 4· MIC and greater, against all organisms with the exception of VRSA PA (8· MIC or greater) and performed similarly in the presence of serum. Time-kill curves with telavancin also demonstrated concentration-dependent activity as displayed in Figure 2 . Significant differences between compounds are noted in Tables 3-5 . In general, telavancin demonstrated significantly greater kill compared with other compounds at low multiples of the MIC (1 and 2·) ; however, at higher concentrations, some variability was noted between organisms but in general no differences were discerned.
Vancomycin demonstrated no activity against either VRSA; while reaching bactericidal activity only at concentrations above targeted serum levels against Mu50 and NJ992. 16 At concentrations of 1 and 2· MIC, neither quinupristin/dalfopristin nor linezolid reached bactericidal activity and in many instances significant regrowth at 24 h was noted. Quinupristin/dalfopristin demonstrated bactericidal activity at concentrations between 4 and 32· MIC for NJ992 and VRSA PA and at 8, 16 and 32· MIC for Mu50 and VRSA MI with levels being consistent with achievable serum concentrations with the exception of 32· MIC against Mu50, NJ992 and VRSA PA . 17 Against VRSA MI , linezolid exhibited bacteriostatic activity at concentrations of 4 and 8· MIC while demonstrating bactericidal activity at concentrations of 16 and 32· MIC although the concentrations utilized are above the achievable concentrations of the drug in serum based upon pharmacokinetic studies. 18 Linezolid was bactericidal at concentrations at or above 4· MIC for VRSA PA , Mu50 and NJ992, of which only 4 and 8· MIC concentrations are achievable with 600 mg twice-daily dosing of linezolid. 18 Daptomycin demonstrated rapid bactericidal activity for all tested organisms at concentrations at or above 4· MIC except for VRSA MI (8· MIC or higher), decreasing to detection limits by 8 h (see Figure 1) . At low multiple concentrations (1 and 2· MIC) regrowth was demonstrated for all organisms with or without serum. In the presence of serum, daptomycin retained rapid bactericidal activity against Mu50 and NJ992 at concentrations above 4· MIC; however, regrowth was noted against VRSA MI and VRSA PA up to 8· MIC, with bactericidal activity being observed at all higher concentrations. No resistance was detected despite the observation of regrowth of the organisms.
Discussion
Antibiotic protein binding and its impact on clinical outcomes has been a controversial subject for a number of years. Biologically, only free drug is available to interact with the targeted bacterial cells, 19, 20 and therefore the per cent free fraction has been utilized in most pharmacodynamic simulations. It has been observed in vitro that the susceptibility profiles of drugs that are highly protein bound (i.e. ‡90%) are affected by the presence of serum or albumin. Although highly variable, a 1-to 8-fold increase in MICs in the presence of serum has been described for antibiotics such as teicoplanin, daptomycin and ceftriaxone against S. aureus. [21] [22] [23] In addition, the degree and association of binding affinity may also play a role. For example, a drug that has a high degree of binding affinity may be less available at the site of infection. Previous investigations have demonstrated that telavancin's protein binding in human serum is 93%. 10 In the present study, telavancin MIC in the presence of serum increased on average 2-fold. Despite the increase in MIC, this effect had no Table 3 . GISS change from baseline (log 10 cfu/mL) at 24 h g Mu50 NJ992 impact on bactericidal activity as demonstrated by kill curves at concentrations of 4· MIC or greater. This may be due to a weaker protein binding association constant than predicted by protein binding experiments. 10, 24 Alternatively, the second mechanism (an effect on bacterial membrane integrity) may be less affected by protein binding, as suggested by Hegde et al. 25 Notably, the concentration-dependent activity of telavancin was apparent both in the presence and absence of serum. The present study evaluated telavancin and comparator agents against a large number of GISS, hGISS and VRSA clinical isolates. The susceptibility data against GISA strains are consistent with previous studies evaluating telavancin, daptomycin and linezolid. [26] [27] [28] In the present study, telavancin demonstrated concentration-dependent activity against GISS, hGISS and VRSA clinical isolates. Telavancin's activity appeared similar to other antimicrobials against the GISS and hGISS as exhibited by killing curve experiments. Some differences between activities were noted against the VRSA compared with daptomycin at serum concentrations achievable with a 12.5 mg/kg dose of telavancin. 10 Similar to daptomycin, the rate of telavancin killing was decreased in the presence of human serum; however, bactericidal activity was maintained. Further investigation of telavancin as an alternative treatment for GISS, hGISS and VRSA infections is warranted.
